September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Diagnostic Innovations in Glaucoma Study (DIGS): Comparing the Rates of Macular Ganglion Cell layer loss in Healthy, non-progressing Glaucoma and progressing glaucoma Eyes
Author Affiliations & Notes
  • Naama Hammel
    Hamilton Glaucoma Center, Department of ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Akram Belghith
    Hamilton Glaucoma Center, Department of ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Felipe A Medeiros
    Hamilton Glaucoma Center, Department of ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Luke Saunders
    Hamilton Glaucoma Center, Department of ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Saif Baig
    Hamilton Glaucoma Center, Department of ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Robert N Weinreb
    Hamilton Glaucoma Center, Department of ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Linda M Zangwill
    Hamilton Glaucoma Center, Department of ophthalmology, University of California, San Diego, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Naama Hammel, None; Akram Belghith, None; Felipe Medeiros, Alcon (C), Allergan, Inc (F), Allergan, Inc (C), Ametek (F), Ametek (C), Bausch & Lomb, Inc (F), Carl-Zeiss Meditec, Inc (F), Carl-Zeiss Meditec, Inc (C), Carl-Zeiss Meditec, Inc (R), Heidelberg Engineering GmbH (F), Heidelberg Engineering GmbH (C), Sensimed, Inc (F), Topcon, Inc (F); Luke Saunders, None; Saif Baig, None; Robert Weinreb, Alcon (C), Allergan (C), Bausch & Lomb (C), Carl Zeiss Meditec (C), Carl Zeiss Meditec (F), Carl Zeiss Meditec (R), Genentech (F), Heidelberg engineering (F), Optovue (F), Topcon (C), Topcon (F); Linda Zangwill, Carl-Zeiss Meditec, Inc (F), Carl-Zeiss Meditec Inc (R), Heidelberg Engineering GmbH (F), Optovue Inc (F), Optovue Inc (R), Quark (F), Topcon Medical Systems Inc (F)
  • Footnotes
    Support  NH Grants EY11008; U10EY14267; EY019869; EY021818; P30EY022589 and participant retention incentive grants in the form of glaucoma medication at no cost from Alcon Laboratories Inc., Allergan Inc., Pfizer Inc., and Santen Inc.; Unrestricted grant from Research to Prevent Blindness, New York, New York.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 373. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Naama Hammel, Akram Belghith, Felipe A Medeiros, Luke Saunders, Saif Baig, Robert N Weinreb, Linda M Zangwill; Diagnostic Innovations in Glaucoma Study (DIGS): Comparing the Rates of Macular Ganglion Cell layer loss in Healthy, non-progressing Glaucoma and progressing glaucoma Eyes. Invest. Ophthalmol. Vis. Sci. 2016;57(12):373.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the rates of ganglion cell layer (GCL) thickness, retinal ganglion cell – inner plexiform layer (GCIPL) thickness and inner plexiform layer (IPL) change over time in healthy and non-progressing glaucoma and progressing glaucoma eyes using a novel cubic thickness grid (Figure 1).

Methods : 57 eyes of 29 healthy subjects and 181 eyes of 96 glaucoma subjects from the Diagnostic Innovations in Glaucoma Study (DIGS) were included. All eyes underwent 24-2 standard automated perimetry (SAP) and spectral-domain optical coherence tomography (Spectralis SD-OCT) high-resolution volume macular scans every 3 months for 2 years. Glaucoma progression was evaluated using Glaucoma Progression Analysis (GPA). The GCL, GCIPL and IPL layer thicknesses were measured using the San Diego Automated Layer Segmentation Algorithm (SALSA). Mixed effects models were used to compare the rate of change.

Results : Mean age was 47 years (range 22.5-66) for healthy subjects and 68 years (32-90) for glaucoma subjects. 22 eyes were detected as progressing using GPA. In healthy eyes, mean rates of GCL, GCIPL and IPL change were -0.073 µm/year, -0.117 µm/year and -0.039 µm/year, respectively; In glaucoma eyes, the rates of change were -0.184 µm/year, -0.25 µm/year and -0.064 µm/year, respectively. In both healthy and glaucoma eyes all GCL, GCIPL and IPL slopes were significantly different from zero. In glaucoma eyes, only the mean rates of GCL and GCIPL change in the nasal inferior sector were significantly faster in progressing glaucoma eyes than non-progressing glaucoma eyes (-0.053 µm/year vs. -0.029 µm/year, P=0.011 and -0.11 µm/year vs. -0.064 µm/year P=0.019 respectively).

Conclusions : In this cohort with relatively short follow-up time, the mean rate of GCL, GCIPL and IPL change was significantly faster in glaucoma eyes than in healthy eyes. In glaucoma eyes, only the mean rates of the GCL and GCIPL in the nasal inferior sector was significantly faster in GPA progressing glaucoma eyes than non-progressing glaucoma eyes. Further prospective clinical cohort studies with longer follow-up are needed to confirm these results.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

Figure 1: 4mm x 4mm Novel Thickness Grid with 1.5mm x 1.5mm center excluded from scan sampling (A) takes into account areas more peripheral to those encompassed by the 3.45mm Standard Thickness Grid (B).

Figure 1: 4mm x 4mm Novel Thickness Grid with 1.5mm x 1.5mm center excluded from scan sampling (A) takes into account areas more peripheral to those encompassed by the 3.45mm Standard Thickness Grid (B).

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×